Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04939090

Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients

Hematopoietic and Lymphoid Cell Neoplasm Clinical Trial

Official title:
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia

Clinical Trial Summary

This phase III trial compares the effects of olanzapine versus megestrol acetate in treating loss of appetite in patients with cancer that has spread to other places in the body (advanced). Olanzapine may stimulate and increase appetite. This study aims to find out if olanzapine is better than the usual approach (megestrol acetate) for stimulating appetite and preventing weight loss.

Clinical Trial Description

The primary and secondary objectives of the study: PRIMARY OBJECTIVE: I. To determine whether olanzapine leads to greater appetite improvement from baseline in cancer patients suffering from anorexia compared to megestrol acetate using the 0-10 numerical rating scale (NRS). SECONDARY OBJECTIVES: I. To determine whether olanzapine leads to a greater proportion of patients who report a 5% or greater weight gain from baseline compared to megestrol acetate. II. To compare change in cachexia/anorexia symptoms with olanzapine compared to megestrol acetate using the Functional Assessment of Anorexia/Cachexia Treatment (FAACT)-Anorexia/Cachexia Subscale (A/CS) instrument. OUTLINE: Patient are randomized to 1 of 2 arms. ARM I: Patients receive olanzapine orally (PO) once daily (QD) for up to 4 weeks in the absence of consent withdrawal or unacceptable toxicity. ARM II: Patients receive megestrol acetate PO QD for up to 4 weeks in the absence of consent withdrawal or unacceptable toxicity. ;

Study Design

Related Conditions & MeSH terms

  • Advanced Malignant Solid Neoplasm
  • Anorexia
  • Hematopoietic and Lymphoid Cell Neoplasm
  • Neoplasms
Clinical Trial Details
NCT number NCT04939090
Study type Interventional
Source Alliance for Clinical Trials in Oncology
Contact Aminah Jatoi, MD
Phone 507-266-9160
Email Jatoi.aminah@mayo.edu
Status Recruiting
Phase Phase 3
Start date January 3, 2022
Completion date December 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT05106374 - Risk of Chemotherapy Toxicity in Older Patients With Blood Cancer or Non-small Cell Lung Cancer
Recruiting NCT05660421 - Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors Phase 2
Suspended NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Completed NCT04666025 - SARS-CoV-2 Donor-Recipient Immunity Transfer
Withdrawn NCT04127721 - Itacitinib for the Prevention of Graft Versus Host Disease in Patients Undergoing Donor Stem Cell Transplantation Phase 2
Active, not recruiting NCT03712878 - 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies Phase 2
Active, not recruiting NCT06062901 - An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors N/A
Terminated NCT04081298 - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors N/A
Completed NCT04983901 - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Phase 2
Recruiting NCT04188912 - Close Assessment and Testing for Chronic Graft Versus Host Disease, CATCH Study
Active, not recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT05112614 - Role of Gut Microbiome in Cancer Therapy
Active, not recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Withdrawn NCT04190433 - Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial Phase 2
Terminated NCT04083170 - Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers Phase 2
Recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A
Withdrawn NCT04820894 - Perception of Cure Among Patients With Metastatic Cancer
Completed NCT03125070 - Self-Management Program and Survivorship Care Plan in Improving the Health of Cancer Survivors After Stem Cell Transplant Phase 3
Completed NCT01664910 - CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies Phase 1/Phase 2